Cue Biopharma to receive $7.5 million milestone payment from Boehringer Ingelheim deal

Cue Biopharma, Inc.

Cue Biopharma, Inc.

CUE

0.00
  • Cue Biopharma will receive a $7.5 million preclinical milestone payment under its collaboration and license agreement with Boehringer Ingelheim.
  • Payment follows Boehringer Ingelheim selection and approval of first compound for lead optimization.
  • Cue expects to receive payment in May 2026.
  • Collaboration terms include eligibility for up to about $337.5 million in additional milestone payments, plus royalties on net sales.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cue Biopharma Inc. published the original content used to generate this news brief on April 08, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.